ReviewCurrent hypertension reports2012
Oxidative stress in the cardiorenal metabolic syndrome.
Review in Current hypertension reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- Serum Copper-to-Zinc Ratio and Oxidative Stress Are Associated with Anemia in Older Adults with Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Article
- Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.Current hypertension reports · 2026Review
- The core mechanism of hypertension-linked renal fibrosis: "RAAS-ROS-inflammation-fibrosis" axis.iScience · 2026Review
- Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review.Journal of clinical medicine · 2026Review
- Eplerenone improves kidney function and cardiac performance in obese male mice.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Dietary antioxidants and CKM-depression comorbidity: a primary analysis with a secondary evaluation of all-cause mortality using six machine learning algorithms.European journal of medical research · 2025Observational
- Dietary antioxidants and mortality in early-stage CKM syndrome: insights from NHANES.Nutrition & metabolism · 2025Article
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.Future cardiology · 2025Review
- Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.Antioxidants (Basel, Switzerland) · 2025Review
- Association of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in population with cardiovascular-kidney-metabolic syndrome stages 0-4: evidence from a large cohort study.Diabetology & metabolic syndrome · 2025Article
- Effect of N-Acetylcysteine in Mitochondrial Function, Redox Signaling, and Sirtuin 3 Levels in the Heart During Cardiorenal Syndrome Type 4 Development.Antioxidants (Basel, Switzerland) · 2025Article
- Association between triglyceride-glucose index and its composite obesity indexes and cardio-renal disease: analysis of the NHANES 2013-2018 cycle.Frontiers in endocrinology · 2025Article
- Endothelial Dysfunction in Obesity and Therapeutic Targets.Advances in experimental medicine and biology · 2024Review
- Article
- Myo-inositol oxygenase accentuates renal tubular injury initiated by endoplasmic reticulum stress.American journal of physiology. Renal physiology · 2019Article
- Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.Physiological reviews · 2018Review
- Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.International journal of hematology · 2016Article
- Cellular apoptosis in the cardiorenal axis.Heart failure reviews · 2016Review
- Biochemical effects of oleuropein in gentamicin-induced nephrotoxicity in rats.ARYA atherosclerosis · 2016Article
- Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?Redox biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Excess visceral adiposity contributes to inappropriate activation of the renin-angiotensin-aldosterone system despite a state of volume expansion and of salt retention that contributes to subclinical elevations of pro-oxidant mechanisms. These adverse effects are mediated by excess generation of reactive oxygen species (ROS) and diminished antioxidant defense mechanisms. Excess tissue (i.e., skeletal muscle, liver, heart) free oxygen radicals contribute to impairments in the insulin-dependent metabolic signaling pathways that regulate glucose utilization/disposal and systemic insulin sensitivity. The generation of ROS is required for normal cell signaling and physiological responses. It is a loss of redox homeostasis that results in a proinflammatory/profibrotic milieu that promotes impairments in insulin metabolic signaling, reduced endothelial-mediated vasorelaxation, and associated cardiovascular and renal structural and functional abnormalities. These maladaptive processes are increasingly recognized as important in the progression of hypertension in the cardiorenal metabolic phenotype. There is increasing evidence to support a critical role for Ang II signaling through the AT(1)R and aldosterone actions through the MR in conjunction with an altered redox-mediating impaired endothelial, cardiac and renal function in this metabolic phenotype. There are emerging clinical data that indicate that therapies that target the renin angiotensin-aldosterone system (RAAS) also attenuate oxidative stress, and improve endothelial, cardiac and renal functions, which collectively contribute to reductions in hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.